BioMarck Pharmaceuticals Ltd.
This article was originally published in Start Up
Executive Summary
BioMarck Pharmaceuticals is studying the role of the MARCKS protein (myristoylated alanine-rich C kinase substrate) in chronic obstructive pulmonary disease and diseases like asthma and cystic fibrosis. In each of these diseases, excessive amounts of mucus are secreted, which leads to obstruction of the lung airways. Experiments in mice showed that inhibiting the protein led to decreased mucus secretion, reduced inflammation in the lungs, and improvements in lung air flow.
You may also be interested in...
Start-Up Previews (05/2008)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "A Brighter Outlook for Cystic Fibrosis Drugs," features profiles of APT Pharmaceuticals, Aridis, and BioMarck Pharmaceuticals. Plus these Start-Ups Across Health Care: Cannasat, Nanobiotix, Reveal Sciences, and Vertebration.
A Brighter Outlook for New Cystic Fibrosis Drugs
The pipeline of new medicines to combat cystic fibrosis has risen dramatically thanks to funding support from philanthropic organizations such as the Cystic Fibrosis Foundation and venture capitalists. As more compounds demonstrate proof-of-concept, look for Big Pharma to move into the area too, lured by the possibility of label expansion beyond CF into more widespread diseases such as asthma and COPD.
Start-Up Previews (05/2008)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "A Brighter Outlook for Cystic Fibrosis Drugs," features profiles of APT Pharmaceuticals, Aridis, and BioMarck Pharmaceuticals. Plus these Start-Ups Across Health Care: Cannasat, Nanobiotix, Reveal Sciences, and Vertebration.